IonQ (IONQ) announced an investment partnership with the Centre for Commercialization of Regenerative Medicine, or CCRM, to accelerate therapeutic development using hybrid quantum and quantum-AI technologies. The partnership includes an investment commitment into CCRM’s new quantum-biotech initiatives and establishes IonQ as the technology partner across CCRM’s global network of therapy hubs. This collaboration will initially focus on areas including bioprocess optimization, disease-modeling workflows, and quantum enhanced simulation to support the design and manufacturing of advanced therapies.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IONQ:
- How Quantum Modeling Helps Companies Cut Costs And Shape Stock Performance Today
- Quantum Computing News: White House Backs Select Firms as Global Quantum Spend and Space Tests Accelerate
- Alphabet CEO Sees Quantum Tech Near Turning Point as Quantum Stocks Exhibit Sharp Swings
- IONQ and QBTS: AI Analyst Boosts Price Targets on Two Key Quantum Stocks but Remains Cautious
- Quantum Computing News: IonQ Expands Aerospace Reach, Japan Builds Secure Network, and Florida Launches Sensor Strategy